Evelo Biosciences (EVLO) Stock Overview

A clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. More details

EVLO fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap ($2K)

Shares are highly illiquid

Latest financial reports are more than a year old

EVLO Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW489,440 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

489,440 investors already sharing narratives

View all narratives

Evelo Biosciences, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Evelo Biosciences
Historical stock prices
Current Share Price	US$0.0001
52 Week High	US$0.0006
52 Week Low	US$0.000001
Beta	0
1 Month Change	-66.67%
3 Month Change	0%
1 Year Change	-80.00%
3 Year Change	-99.90%
5 Year Change	-99.90%
Change since IPO	-99.90%

Recent updates

Analysis Article • Aug 18

Is Evelo Biosciences (NASDAQ:EVLO) Using Debt In A Risky Way?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Seeking Alpha • Aug 11

Evelo Biosciences GAAP EPS of -$0.40 beats by $0.03

Evelo Biosciences press release (NASDAQ:EVLO): Q2 GAAP EPS of -$0.40 beats by $0.03. As of June 30, 2022, cash and cash equivalents were $92.0M, as compared to cash and cash equivalents of $68.4M as of December 31, 2021.

Seeking Alpha • Jul 18

Marella Thorell is the new finance chief of Evelo Biosciences

Evelo Biosciences (NASDAQ:EVLO) appoints 25 years of finance and operations experienced Marella Thorell as CFO, effective September 1, 2022. Most recently she served as Chief Accounting Officer and previously as Head of Finance of Centessa Pharmaceuticals.

Seeking Alpha • Jun 06

Evelo Biosciences: Hope After Dilution?

Today, we put Evelo Biosciences in the spotlight for the first time. The company has several potential catalysts on the horizon. The company also recently executed a large direct offering and brought aboard some strategic advisors as well. A full investment analysis follows in the paragraphs below.

Analysis Article • Mar 21

Evelo Biosciences (NASDAQ:EVLO) Has Debt But No Earnings; Should You Worry?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Analysis Article • Sep 25

Is Evelo Biosciences (NASDAQ:EVLO) Weighed On By Its Debt Load?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Analysis Article • Mar 11

What Type Of Shareholders Make Up Evelo Biosciences, Inc.'s (NASDAQ:EVLO) Share Registry?

If you want to know who really controls Evelo Biosciences, Inc. ( NASDAQ:EVLO ), then you'll have to look at the makeup...

Analysis Article • Dec 15

Trade Alert: The Independent Chairman Of Evelo Biosciences, Inc. (NASDAQ:EVLO), David Epstein, Has Just Spent US$51k Buying 77% More Shares

Whilst it may not be a huge deal, we thought it was good to see that the Evelo Biosciences, Inc. ( NASDAQ:EVLO...

Analysis Article • Dec 11

Do Institutions Own Evelo Biosciences, Inc. (NASDAQ:EVLO) Shares?

A look at the shareholders of Evelo Biosciences, Inc. ( NASDAQ:EVLO ) can tell us which group is most powerful. Large...

Shareholder Returns

	EVLO	US Biotechs	US Market
7D	9,900.0%	-2.4%	0.7%
1Y	-80.0%	35.9%	20.6%

Return vs Industry: EVLO underperformed the US Biotechs industry which returned 36.1% over the past year.

Return vs Market: EVLO underperformed the US Market which returned 19.5% over the past year.

Price Volatility

Is EVLO's price volatile compared to industry and market?
EVLO volatility
EVLO Average Weekly Movement	n/a
Biotechs Industry Average Movement	10.4%
Market Average Movement	7.3%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.2%

Stable Share Price: EVLO's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine EVLO's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2014	n/a	n/a	n/a

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriasis . The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology.

Evelo Biosciences, Inc. Fundamentals Summary

How do Evelo Biosciences's earnings and revenue compare to its market cap?
EVLO fundamental statistics
Market cap	US$1.90k
Earnings (TTM)	-US$82.35m
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is EVLO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EVLO income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$82.35m
Earnings	-US$82.35m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did EVLO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/11 03:34
End of Day Share Price	2026/07/08 00:00
Earnings	2023/09/30
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Evelo Biosciences, Inc. is covered by 12 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Matthew Luchini	BMO Capital Markets Equity Research
Gary Nachman	BMO Capital Markets Equity Research
Clarence Powell	BMO Capital Markets Equity Research

Evelo Biosciences (EVLO) Stock Overview

Risk Analysis

Join community and earn perks

Evelo Biosciences, Inc. Competitors

Vincerx Pharma

Synairgen

Beroni Group

Lipella Pharmaceuticals

Price History & Performance

Recent News & Updates

Evelo Biosciences, Inc. Files Form 15

Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from S&P TMI Index

Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from NASDAQ Biotechnology Index

Evelo Biosciences Provides Non-Compliance Update

Evelo Biosciences, Inc. Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis

Evelo Biosciences, Inc. announced that it has received $25.468522 million in funding from FMR LLC, Flagship Pioneering

Recent updates

Evelo Biosciences, Inc. Files Form 15

Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from S&P TMI Index

Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from NASDAQ Biotechnology Index

Evelo Biosciences Provides Non-Compliance Update

Evelo Biosciences, Inc. Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis

Evelo Biosciences, Inc. announced that it has received $25.468522 million in funding from FMR LLC, Flagship Pioneering

Evelo Biosciences, Inc. Announces Management Changes

Evelo Biosciences Announces Reverse Stock Split to Meet the Minimum Per Share Bid Price Requirement for Continued Listing on the Nasdaq Global Select Market

Evelo Biosciences, Inc. Eliminates Position of Jonathan Zung, Chief Development Officer

David R. Epstein Intends to Resign from Evelo Biosciences, Inc.'s Board

Evelo Biosciences, Inc. Announces Executive Changes

Evelo Biosciences, Inc. Announces Updates to its Clinical Pipeline

Price target decreased to US$8.00

High number of new directors

Is Evelo Biosciences (NASDAQ:EVLO) Using Debt In A Risky Way?

Evelo Biosciences, Inc. Plans to Replace President Simba Gill

Evelo Biosciences, Inc. Announces Two Phase 2 Clinical Read-Outs with EDP1815 in Atopic Dermatitis Expected in First quarter and Second Quarter 2023; Phase 2 Data for EDP2939 in Psoriasis expected in Second Half 2023

Evelo Biosciences GAAP EPS of -$0.40 beats by $0.03

Evelo Biosciences, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Evelo Biosciences, Inc. Appoints Marella Thorell as the Chief Financial Officer Effective from September 1, 2022

Marella Thorell is the new finance chief of Evelo Biosciences

Evelo Biosciences, Inc.(NasdaqGS:EVLO) dropped from Russell 2000 Dynamic Index

Evelo Biosciences: Hope After Dilution?

Evelo Biosciences, Inc. Announces Executive Changes

High number of new directors

High number of new directors

Price target decreased to US$15.40

David P. Perry Not Stand for Re-Election to Board of Directors of Evelo Biosciences, Inc

Evelo Biosciences, Inc. Plans to Meet with Health Authorities to Discuss the Path Forward to Registration Trials for EDP1815 in Patients with Psoriasis

Price target increased to US$22.50

Evelo Biosciences, Inc. Announces Executive Appointments

Evelo Biosciences (NASDAQ:EVLO) Has Debt But No Earnings; Should You Worry?

Evelo Biosciences, Inc. Announces Data from Post-Treatment Follow-Up (Part B) of its Phase 2 Trial of EDP1815 in Mild and Moderate Psoriasis

Evelo Biosciences Announces Dosing of First Patient in Phase 2 Trial of EDP1815 in Atopic Dermatitis

Evelo Biosciences Announces Highly Significant Reductions in Clinically Validated Inflammatory Cytokines in Edp1815 Phase 2 Psoriasis Trial

Price target increased to US$23.70

Evelo Biosciences Presents Data on EDP1815 Mechanism of Action and Supporting Ongoing Clinical Development for Inflammatory Diseases

Evelo Biosciences, Inc. Announces Updates of Phase 2 Clinical Trial of EDP1815 in Atopic Dermatitis and Phase 1B Clinical Data with EDP1815 in Atopic Dermatitis

High number of new directors

High number of new directors

Evelo Biosciences, Inc. Announces Positive Data from Its Phase 2 Study Evaluating EDP1815 Versus Placebo for the Treatment of Mild and Moderate Psoriasis

Is Evelo Biosciences (NASDAQ:EVLO) Weighed On By Its Debt Load?

Price target increased to US$23.33

Evelo Biosciences Presents New Preclinical Data for Extracellular Vesicle Anti-Inflammatory Product Candidate Edp2939 at the American Association of Immunologists Meeting

What Type Of Shareholders Make Up Evelo Biosciences, Inc.'s (NASDAQ:EVLO) Share Registry?

Evelo Biosciences, Inc. to Report Q4, 2020 Results on Mar 09, 2021

Appoints John A. Hohneker, M.D. to Board of Directors

Evelo Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $67.5 million.

New 90-day high: US$18.60

Evelo Biosciences, Inc. Updates Data Following Completion of the Mild and Moderate Atopic Dermatitis Cohort in Its Phase 1B Clinical Trial

New 90-day high: US$13.89

Evelo Biosciences Expands Clinical Programs

New 90-day high: US$12.28

Evelo Biosciences, Inc. Appoints Jonathan Zung as Chief Development Officer

Evelo Biosciences, Inc. Enters into Development and Clinical Master Services Agreement with Halo Pharmaceutical, Inc

Evelo Biosciences, Inc. Updates on Its Clinical Trails

Independent Chairman recently bought US$51k worth of stock

Trade Alert: The Independent Chairman Of Evelo Biosciences, Inc. (NASDAQ:EVLO), David Epstein, Has Just Spent US$51k Buying 77% More Shares

Evelo Biosciences, Inc. Reports Positive Topline Clinical Data in Phase 1b Trial of EDP1815 in Atopic Dermatitis

Do Institutions Own Evelo Biosciences, Inc. (NASDAQ:EVLO) Shares?

Price target raised to US$9.67

New 90-day high: US$6.41

Evelo Biosciences Completes Enrollment to Interim Target in Phase 2 Trial Evaluating EDP1815 for the Treatment of Psoriasis